Tumor markers classification

Alaiya AA et al. Cancer proteomics from identification of novel markers to creation of artificial learning models for tumor classification. Electrophoresis 2000 21 1210-1217. 

It is the goal of array-based prognostics to utilize a panel of markers that are more accurately able to stratify patients into prognostic groupings. There are several examples in the literature of biomarker panels identified by microarray analysis that may have some relation to prognostic outcome (4, 77, 78, 79,80). However, the issue remains that many of these biomarker panels do not afford sufficient specificity or sensitivity to warrant clinical application. Microarrays offer the potential to profile tumors at a finer level of detail than what can be obtained by the pathologist however, it is the reliance on classification from traditional pathology that has confounded many studies. 

Juhlin CC, Villablanca A, Sandelin K, et al. Parafibromin immunoreactivity its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer. 2007 14 501-512. 

Likewise, newer immunohistochemical (IHC) and molecular markers in bladder and testicular tumors are increasingly used for reaching an accurate diagnosis and classification. The following is a discussion of the utility of immunohistochemical markers, genomic applications, and prognostic aspects of urologic and testicular tumors. 

Zhang J, Dalton J, Ftrller C. Epithelial marker-negative desmoplastic small round cell tumor with atypical morphology definitive classification by fluorescence in situ hybridization. Arch Pathol Lab Med. 2007 131 646-649. 

---